| Modern Day Health Care Prof Llc | |
|
1206 S Main St Aberdeen SD 57401-7071 | |
| (605) 250-1200 | |
| (605) 250-0999 |
| Full Name | Modern Day Health Care Prof Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 1206 S Main St, Aberdeen, South Dakota |
| Authorized Official Name and Position | Deanne Donaway (CEO) |
| Authorized Official Contact | 6052145762 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Modern Day Health Care Prof Llc 2501 S Louise Ave Unit 90332 Sioux Falls SD 57109-4669 Ph: (605) 250-1200 | Modern Day Health Care Prof Llc 1206 S Main St Aberdeen SD 57401-7071 Ph: (605) 250-1200 |
| NPI Number | 1851883540 |
|---|---|
| Provider Enumeration Date | 05/30/2018 |
| Last Update Date | 03/27/2023 |
| Medicare PECOS PAC ID | 8325473507 |
|---|---|
| Medicare Enrollment ID | O20200116000301 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851883540 | NPI | - | NPPES |
| Provider Name | Angela K Gaikowski |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275788960 PECOS PAC ID: 9032339510 Enrollment ID: I20141006000093 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Jenna Braun |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942792411 PECOS PAC ID: 3173856317 Enrollment ID: I20190605000715 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Amanda Marie Sneed |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932722840 PECOS PAC ID: 2163847252 Enrollment ID: I20200806001932 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Lindsay D Peterson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518575174 PECOS PAC ID: 1355769621 Enrollment ID: I20200918000292 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Mark R Hager |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1952397499 PECOS PAC ID: 7911192745 Enrollment ID: I20210127002724 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Kelcey Geditz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710570148 PECOS PAC ID: 7911314703 Enrollment ID: I20210323000648 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Jocelyn Reints |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114383262 PECOS PAC ID: 1850798166 Enrollment ID: I20210928003384 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Jenny A Schaeffer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457893604 PECOS PAC ID: 2264830405 Enrollment ID: I20211001002164 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Jamie Forrest |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669141180 PECOS PAC ID: 1850799826 Enrollment ID: I20211005001856 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Contessa Marie Windeshausen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558134551 PECOS PAC ID: 3971954678 Enrollment ID: I20240108000071 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
| Provider Name | Margaret Courtney Harlow |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407627722 PECOS PAC ID: 5092158451 Enrollment ID: I20240213002342 |
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
News Archive
Cells have the remarkable ability to keep track of their genetic contents and - when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has signed a definitive agreement to acquire Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).
In the neural train wreck that is stroke, the cutoff of oxygen kills brain cells through a buildup of acid, as well as by overexciting receptors on the surface of brain cells.
› Verified 2 days ago
Avera Aberdeen Family Physicians Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 105 S State St Ste 113, Aberdeen, SD 57401 Phone: 605-225-0378 Fax: 605-225-7919 | |
Aberdeen Community Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 506 S Wilson St, Aberdeen, SD 57401 Phone: 605-725-3900 Fax: 605-725-3901 | |
Kathleen Van De Walle Do Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1314 N Main St, Aberdeen, SD 57401 Phone: 605-229-3682 | |
Aberdeen Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 201 S Lloyd St, Suite W270, Aberdeen, SD 57401 Phone: 605-225-4070 Fax: 605-725-2416 | |
Tiny Knight Safety And Assurance Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 202 S Main St Ste 530, Aberdeen, SD 57401 Phone: 605-216-9777 | |
Sanford Aberdeen Cardiology Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3015 3rd Ave Se, Aberdeen, SD 57401 Phone: 605-226-5500 Fax: 605-226-5601 | |
Internal Medicine Associates Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 201 S Lloyd St, Suite E101, Aberdeen, SD 57401 Phone: 605-225-8800 Fax: 605-225-1302 |